Wutah pendapatan taun lumaku: FSD Pharma, Inc. (HUGE)

Tandha merek FSD Pharma (HUGE)

The absence of commercial products leads to a continuous cash burn on research and development for FSD Pharma Inc. (HUGE). Relative year-over-year (LTM) revenue dynamics visualize this cash deficit, where 0.00 captures the magnitude of this parameter. The Canadian enterprise relies on biotechnology for brain therapy, and the drug Lucid-MS targets myelin regeneration in multiple sclerosis to restore lost functions to patients.

FSD Pharma (HUGE): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 20.02.2024

Ringkesan rincian data analitis FSD Pharma, Inc. (HUGE)

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:FSD Pharma Inc. - HUGE
Produk dadi FSD Pharma

This indicator measures rolling year revenue dynamics, neutralizing short-term volatility and revealing real trends in business operational efficiency. For FSD Pharma Inc. (HUGE), the rolling year-over-year revenue growth chart is critically important, as it reflects the commercialization of R&D developments under strict FDA regulation and patent protection for multiple sclerosis therapy.